Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-06
2005-09-06
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S048000, C544S183000, C544S287000, C514S243000, C514S266220, C546S120000
Reexamination Certificate
active
06939870
ABSTRACT:
A compound represented by the formula I:wherein A represents the following heterocycles:and R1-9are as defined herein, a composition containing this compound and methods for treating disorders of the serotonin-affected neurological systems utilizing such a compound or composition.
REFERENCES:
patent: 6 662 58 (1995-08-01), None
Abdulqader, A., et al., “Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs,”J. Med. Chem., 1985, 28, 1394-1398.
Arborelius, L., et al., “5-HT1Areceptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram,”Naunyn-Schmiedeberg's Arch Pharmacol., 1995, 352, 157-165.
Armarego, W.L.F., “Improved preparation of phthalazine and quinazoline,”J. Appl. Chem., Feb. 1961, 11, 70-72.
Artigas, F., et al., “Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors,”Arch Gen Psychiatry, Mar. 1994, 51, 248-251.
Cheetham, S.C., et al., “[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various anti-depressant treaments,”Neuropharmacol., 1993, 32(8), 737-743.
Cheng, Y.-C., et al., “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction,”Biochem. Pharmacol., 1973, 22, 3099-3108.
Hall, M.D., et al., “[3H]8-hydroxy-2-(Di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain,”J. Neurochem., 1985, 44(6), 1685-1696.
Invernizzi, R., et al., “Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1Areceptors,”Eur. J. Pharmaco., 1994, 260, 243-246.
Kobylecki, R.J., et al., Advances in Heterocyclic Chemistry,Academic Press, 1976 Katritzky, A.R., et al. (Eds.), 19, 215-277.
Lazareno, S., et al., “Pharmacological characterization of acetylcholine-stimulated [35S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies,”Br. J. Pharmacol., 1993, 109, 1120-1127.
Malleron, J.-L., et al., “New indole derivatives as potent and selective serotonin uptake inhibitors,”J. Med. Chem., 1993, 36, 1194-1202.
Wustrow, D.J., et al., “3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists,”J. Med. Chem., 1997, 40, 250-259.
Davis Jamie M.
Gu Yansong
Venkatesan Aranapakam M.
Berch Mark L.
Habte Kahsay
Woodcock & Washburn LLP
Wyeth
LandOfFree
Substituted-3-indolyl-4-piperidino-alkyl heterocycles for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted-3-indolyl-4-piperidino-alkyl heterocycles for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted-3-indolyl-4-piperidino-alkyl heterocycles for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3443343